Wilmington Savings Fund Society FSB Makes New $1.18 Million Investment in Boston Scientific Co. (NYSE:BSX)

Wilmington Savings Fund Society FSB acquired a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 14,018 shares of the medical equipment provider's stock, valued at approximately $1,175,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. CRA Financial Services LLC grew its stake in Boston Scientific by 4.3% during the 3rd quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider's stock worth $238,000 after buying an additional 117 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in Boston Scientific by 9.7% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock worth $115,000 after buying an additional 119 shares during the last quarter. Adero Partners LLC grew its stake in Boston Scientific by 3.6% during the 3rd quarter. Adero Partners LLC now owns 3,617 shares of the medical equipment provider's stock worth $303,000 after buying an additional 127 shares during the last quarter. Ashton Thomas Securities LLC grew its stake in Boston Scientific by 1.3% during the 3rd quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider's stock worth $835,000 after buying an additional 129 shares during the last quarter. Finally, Jacobsen Capital Management boosted its position in Boston Scientific by 4.9% during the 3rd quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider's stock worth $236,000 after acquiring an additional 133 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the transaction, the executive vice president now owns 34,748 shares in the company, valued at approximately $2,913,967.28. The trade was a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the sale, the chief executive officer now owns 1,572,096 shares of the company's stock, valued at $133,046,484.48. This represents a 9.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 328,157 shares of company stock valued at $27,957,676 in the last three months. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

BSX stock traded down $0.31 on Friday, hitting $90.11. The company had a trading volume of 3,181,520 shares, compared to its average volume of 5,970,553. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $54.95 and a 12-month high of $91.93. The stock has a market cap of $132.81 billion, a price-to-earnings ratio of 74.47, a P/E/G ratio of 2.67 and a beta of 0.80. The stock's 50-day simple moving average is $87.98 and its 200 day simple moving average is $81.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company's revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm earned $0.50 EPS. As a group, equities research analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on BSX. TD Cowen boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday. Stifel Nicolaus upped their price objective on Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a report on Friday, October 18th. Barclays upped their price objective on Boston Scientific from $78.00 to $86.00 and gave the company an "overweight" rating in a report on Thursday, August 22nd. Canaccord Genuity Group upped their price objective on Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, Truist Financial upped their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, October 14th. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.43.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.